Tapering and Sustained Remission of Thrombopoietin Receptor Agonists (TPO-RAs): Is it Time for Paediatric ITP?

• Published in: Advances in therapy 2024-10, Vol.41 (10), p.3771-3777
• Main Authors: Marcos-Peña, Susana, Fernández-Pernia, Beatriz, Provan, Drew, González-López, Tomás José
• Format: Article
• Language: English
• Subjects: Benzoates - therapeutic use; Cardiology; Child; Drug Administration Schedule; Endocrinology; Humans; Hydrazines - therapeutic use; Internal Medicine; Medicine; Medicine & Public Health; Oncology; Pharmacology/Toxicology; Platelet Count; Purpura, Thrombocytopenic, Idiopathic - drug therapy; Pyrazoles - therapeutic use; Receptors, Fc - therapeutic use; Receptors, Thrombopoietin - agonists; Recombinant Fusion Proteins - administration & dosage; Recombinant Fusion Proteins - therapeutic use; Remission Induction; Review; Rheumatology; Thiazoles - therapeutic use; Thiophenes; Thrombopoietin - therapeutic use; Treatment Outcome
• ISSN: 0741-238X; 1865-8652; 1865-8652
• DOI: 10.1007/s12325-024-02951-5

Thrombopoietin receptor agonists (TPO-Ras; romiplostim/eltrombopag/avatrombopag) have demonstrated high efficacy rates (59–88%) and a good safety profile in clinical trials with adult patients with immune thrombocytopenia (ITP). Similar efficacy and safety results have been observed with romiplostim and eltrombopag in paediatric cohorts. Continuous treatment with TPO-RAs has shown durable responses with long-term use, up to 3 years. The effect of TPO-RAs was generally considered transient, as platelet counts tended to drop to baseline values after a short period of time (about 2 weeks), unless treatment was maintained. Several groups have reported successful discontinuation of TPO-RAs without the need for concomitant treatments. This is referred to as sustained remission off treatment (SROT). Both short- and medium-term treatment with TPO-RAs may reduce costs to our healthcare systems and, more importantly, may reduce the potential side effects that may be associated with continuous TPO-RA treatment. The issue of tapering and discontinuation of TPO-RAs in paediatric patients with ITP has received little attention to date. Given that paediatric ITP has much higher rates of spontaneous remission than ITP in adults, we consider that the possibility of SROT of TPO-RAs in paediatric patients with ITP is a neglected but very relevant issue in this subtype of the disease.